Compare VTGN & OMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTGN | OMH |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 24.4M |
| IPO Year | 2014 | 2022 |
| Metric | VTGN | OMH |
|---|---|---|
| Price | $0.26 | $0.42 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $0.90 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 80.5K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | $28.40 |
| Revenue Next Year | $353.99 | $23.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.32 |
| 52 Week High | $5.14 | $1.91 |
| Indicator | VTGN | OMH |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 33.57 |
| Support Level | $0.20 | N/A |
| Resistance Level | $0.66 | $1.38 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 10.27 | 27.33 |
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.